Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial

Gluz, O.; Kuemmel, S.; Nitz, U.; Braun, M.; Luedtke-Heckenkamp, K.; von Schumann, R.; Darsow, M.; Forstbauer, H.; Potenberg, J.; Uleer, C.; Grischke, E. M.; Aktas, B.; Schumacher, C.; zu Eulenburg, C.; Kates, R.; Jozwiak, K.; Graeser, M.; Wuerstlein, R.; Baehner, R.; Christgen, M.; Kreipe, H. H.; Harbeck, N.

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial

Author:

Gluz, O.; Kuemmel, S.; Nitz, U.; Braun, M.; Luedtke-Heckenkamp, K.; von Schumann, R.; Darsow, M.; Forstbauer, H.; Potenberg, J.; Uleer, C.; Grischke, E. M.; Aktas, B.; Schumacher, C.; zu Eulenburg, C.; Kates, R.; Jozwiak, K.; Graeser, M.; Wuerstlein, R.; Baehner, R.; Christgen, M.; Kreipe, H. H.; Harbeck, N.

Tübinger Autor(en):

Grischke, Eva-Maria

Published in:

Annals of Oncology (2023), Bd. 34, H. 6, S. 531-542

Verlagsangabe:

Amsterdam : Elsevier

Language:

English

Full text:

http://dx.doi.org/10.1016/j.annonc.2023.04.002

ISSN:

0923-7534